title: Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers.
abstract: In order to gain new insights into the risk factors influencing human-T-cell-leukemia/lymphoma-virus-type-I (HTLV-I) mother-to-child transmission, a retrospective study of HTLV-I infection among children born to HTLV-I-seropositive women was carried out in a highly HTLV-I-endemic population of African origin living in French Guyana. The study covered 81 HTLV-I-seropositive mothers and their 216 children aged between 18 months old and 12 years old. All plasma samples were tested for the presence of HTLV-I antibodies by ELISA, immunofluorescence assay and Western blot. HTLV-I provirus was detected, in the DNA extracted from peripheral-blood mononuclear cells, by polymerase chain reaction (PCR) using primers specific for 3 different HTLV-I genomic regions (LTR, gag and pX) and quantified by a competitive PCR assay. Out of the 216 children, 21 were found to be HTLV-I-seropositive, giving a crude HTLV-I transmission rate of 9.7%, while among the 180 breast-fed children 10.6% were HTLV-I-seropositive. Perfect concordance between serological and PCR results was observed, and none of the 195 HTLV-I-negative children was found HTLV-I-positive by PCR. In conditional (by family) logistic-regression models, HTLV-I seropositivity in children was associated with an elevated maternal anti-HTLV-I-antibody titer (OR 2.2, p = 0.0013), a high maternal HTLV-I proviral load (OR 2.6, p = 0.033) and child's gender, girls being more frequently HTLV-I-infected than boys: OR 3.6, p = 0.0077 in the model including maternal anti-HTLV-I-antibody titer and OR 4.1, p = 0.002 in the model including the maternal HTLV-I proviral load.
authors.affiliation: Unité d'Epidémiologie des Virus Oncogènes, Institut Pasteur, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Ureta-Vidal
authors.forename: C
authors.initials: C
authors.lastname: Angelin-Duclos
authors.forename: P
authors.initials: P
authors.lastname: Tortevoye
authors.forename: E
authors.initials: E
authors.lastname: Murphy
authors.forename: J F
authors.initials: JF
authors.lastname: Lepère
authors.forename: R P
authors.initials: RP
authors.lastname: Buigues
authors.forename: N
authors.initials: N
authors.lastname: Jolly
authors.forename: M
authors.initials: M
authors.lastname: Joubert
authors.forename: G
authors.initials: G
authors.lastname: Carles
authors.forename: J F
authors.initials: JF
authors.lastname: Pouliquen
authors.forename: G
authors.initials: G
authors.lastname: de Thé
authors.forename: J P
authors.initials: JP
authors.lastname: Moreau
authors.forename: A
authors.initials: A
authors.lastname: Gessain
mesh_terms: D001942:Breast Feeding; D002353:Carrier State / Q000821:virology*; D002648:Child; D002675:Child, Preschool; D004279:DNA, Viral / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005616:French Guiana; D016679:Genome, Viral; D015481:HTLV-I Antibodies / Q000097:blood*; D015490:HTLV-I Infections / Q000097:blood / Q000635:transmission*; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood / Q000821:virology*; D011533:Proviruses / Q000235:genetics / Q000302:isolation & purification; D012189:Retrospective Studies; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D015481:HTLV-I Antibodies